Amgen today announced the submission of a sNDA to the U.S. FDA and a variation to the marketing application to the EMA to include OS data from the Phase 3 head-to-head ENDEAVOR trial in the product information for KYPROLIS® (carfilzomib).

A new multimillion pound collaborative research project led by BP and The University of Manchester could help to dramatically reduce the impact corrosion has on industry worldwide.